Laura Bau
Overview
Explore the profile of Laura Bau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Jorge F, Fernandez-Velasco J, Villarrubia N, Gracia-Gil J, Fernandez E, Meca-Lallana V, et al.
Front Immunol
. 2025 Jan;
15:1535051.
PMID: 39749346
[This corrects the article DOI: 10.3389/fimmu.2024.1480676.].
2.
Rodriguez-Jorge F, Fernandez-Velasco J, Villarrubia N, Gracia-Gil J, Fernandez E, Meca-Lallana V, et al.
Front Immunol
. 2024 Nov;
15:1480676.
PMID: 39606235
Objective: To ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing-remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association...
3.
Bau L, Matas E, Romero-Pinel L, Leon I, Munoz-Vendrell A, Arroyo-Pereiro P, et al.
Neurol Sci
. 2024 Sep;
46(1):335-342.
PMID: 39285108
Background: People with multiple sclerosis (MS) present varying degrees of disability throughout their disease course. The Multiple Sclerosis Severity Score (MSSS) and the Age-Related Multiple Sclerosis Severity Score (ARMSSS) adjust...
4.
Arroyo Pereiro P, Munoz-Vendrell A, Leon Moreno I, Bau L, Matas E, Romero-Pinel L, et al.
J Neurol
. 2023 Dec;
271(4):1599-1609.
PMID: 38085343
Background And Objectives: Serum biomarkers are emerging as useful prognostic tools for multiple sclerosis (MS); however, long-term studies are lacking. We aimed to evaluate the long-term prognostic value of the...
5.
Arroyo-Pereiro P, Garcia-Serrano L, Morandeira F, Urban B, Mas V, Framil M, et al.
Front Immunol
. 2023 Oct;
14:1223514.
PMID: 37885887
Introduction: The role of the kappa-free light chain (kFLC) in the diagnosis of multiple sclerosis (MS) and, to a lesser extent, its role as a medium-term prognostic marker have been...
6.
Lombardo-Del Toro P, Bragado-Trigo I, Arroyo P, Tena-Cucala R, Bau L, Matas E, et al.
J Neurol
. 2023 Jul;
270(11):5196-5200.
PMID: 37460853
No abstract available.
7.
Munoz-Vendrell A, Arroyo-Pereiro P, Leon I, Bau L, Matas E, Martinez-Yelamos A, et al.
J Neurol
. 2023 Mar;
270(5):2559-2566.
PMID: 36913038
Background: Natalizumab (NTZ) and ocrelizumab (OCR) can be used for the treatment of relapsing-remitting multiple sclerosis (RRMS). In patients treated with NTZ, screening for JC virus (JCV) is mandatory, and...
8.
Arroyo-Pereiro P, Munoz-Vendrell A, Bau L, Matas E, Romero-Pinel L, Martinez-Yelamos A, et al.
Eur Neurol
. 2022 Dec;
86(1):73-77.
PMID: 36470228
Introduction: Prior studies have suggested that cardiovascular risk factors (CVRFs) can affect the prognosis of multiple sclerosis (MS). The aim of this study was to assess if CVRFs affect the...
9.
Romero-Pinel L, Bau L, Matas E, Leon I, Munoz-Vendrell A, Arroyo P, et al.
Mult Scler Relat Disord
. 2022 Aug;
68:104103.
PMID: 36029708
Background: Patients with relapsing-remitting multiple sclerosis (RRMS) most commonly experience their first symptoms between 20 and 40 years of age. The objective of this study was to investigate how the...
10.
Romero-Pinel L, Bau L, Matas E, Leon I, Juvany R, Jodar R, et al.
PLoS One
. 2022 Apr;
17(4):e0267504.
PMID: 35486620
Background: The efficacy and safety of disease-modifying therapies (DMTs) in multiple sclerosis (MS) are well known; however, owing to their high costs, determining real-world outcomes is essential to evaluate the...